登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603585 证券简称：苏利股份公告编号：2025-086 转债代码：113640 转债简称：苏利转债 江苏苏利精细化工股份有限公司 关于持股5%以上股东及其一致行动人权益变动 触及1%刻度的提示性公告 相关股东保证向本公司提供的信息真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： ■ 一、信息披露义务人及其一致行动人的基本信息 ■ 2.信息披露义务人信息 ■ 3.一致行动人信息 ■ 二、权益变动触及1%刻度的基本情况 江苏苏利精细化工股份有限公司（以下简称"公司"）于2025年11月5日披露了《江苏苏利精细化工股份 有限公司关于持股5%以上股东减持股份计划公告》（公告编号：2025-084），因自身资金需求，公司 持股5%以上股东江苏沽盛投资有限公司（以下简称"沽盛投资"）拟于2025年11月27日至2026年2月26日 期间通过集中竞价交易方式减持所持有的公司股票，减持数量不超过90万股（占总股本的0.4816%）。 公司于2025年12月18日收到沽盛投资 ...

Core Viewpoint - The announcement from Junshi Bioscience indicates that shareholder Tan Ying Investment plans to reduce its stake by up to 20.53 million shares, representing 2% of the total share capital, through block trading between January 13, 2026, and April 10, 2026, due to fund duration and liquidity arrangements [1]. Group 1: Shareholder Actions - Tan Ying Investment currently holds 59.45 million shares, accounting for 5.79% of the total share capital [1]. - The initial holding of Tan Ying Investment was 71.45 million shares, which represented 6.96% of the total share capital [2]. - Since June 20, 2025, Tan Ying Investment has cumulatively reduced its holdings by 12 million shares, realizing approximately 526 million yuan [2]. Group 2: Financial Performance - For the period from January to September 2025, Junshi Bioscience reported revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, reflecting a year-on-year growth of 35.72% [3]. - As of September 30, 2025, the number of shareholders for Junshi Bioscience was 35,900, an increase of 15.17% from the previous period [3]. Group 3: Market Performance - As of the latest report, Junshi Bioscience's stock price has decreased by 1.42%, with a trading volume of 173 million yuan and a turnover rate of 0.63%, bringing the total market capitalization to 36.478 billion yuan [3]. - The stock has experienced a 30% increase year-to-date, but has seen declines of 2.15% over the last five trading days, 3.50% over the last 20 days, and 22.15% over the last 60 days [3].

毕得医药公告，公司股东李怡静、陈俊、李黎、杜鹃、李爱飞、耿勇、蒋亚妹于2025年9月18日至2025 年12月17日期间合计减持公司股份437,902股，占公司总股本的0.48%。其中，李怡静减持91,673股，减 持价格区间为75.00元/股至82.00元/股，减持总金额为7,245,513元；陈俊减持136,395股，减持价格区间 为70.56元/股至77.80元/股，减持总金额为9,931,500元；李黎减持10,000股，减持价格区间为66.65元/股 至82.20元/股，减持总金额为796,133元；杜鹃减持56,500股，减持价格区间为72.00元/股至76.00元/股， 减持总金额为3,800,000元；李爱飞减持63,255股，减持价格区间为78.50元/股至82.00元/股，减持总金额 为4,991,075元；耿勇减持32,119股，减持价格区间为65.20元/股至81.12元/股，减持总金额为2,404,480 元；蒋亚妹减持47,960股，减持价格区间为77.04元/股至79.03元/股，减持总金额为3,747,171元。 ...

君实生物公告称，截至公告披露日，持股5.7914%的股东上海檀英，因基金期限与流动性资金安排，计 划在2026年1月13日至4月10日，通过大宗交易方式减持不超20,533,797股，即不超公司总股本2%。上海 檀英及一致行动人合计持股7.3263%，其在过去12个月内已减持公司1.1688%股份。本次减持计划存在 不确定性，但不会导致公司控制权变更，也不会对公司经营产生重大影响。 ...

海南瑞泽公告称，公司股票在2025年12月16 - 18日连续三个交易日内日收盘价格跌幅偏离值累计达 20%，属异常波动。经自查，公司前期信息无更正补充，未现重大未公开信息，经营及环境无重大变 化，实控人无应披露重大事项，异常波动期间实控人未买卖股票。另外，副总经理于清池已完成减持 23.1万股计划。截至公告披露日，实控人及其一致行动人质押比例高，存在质押逾期、司法冻结及平 仓、司法拍卖风险。 ...

Core Points - Alibaba's investment arm, Ali Venture, has reduced its stake in Huayi Brothers, dropping its combined holding with Jack Ma from 6.064215% to 4.999996%, officially exiting the major shareholder category [1] - Ali Venture sold 29.5268 million shares at a price of 2.11 yuan per share, raising approximately 62.3 million yuan, with the shares coming from earlier private placements [1] - Huayi Brothers emphasized that this reduction is based on Ali Venture's own business arrangements and will not adversely affect the company's normal operations or control [1] Financial Performance - Huayi Brothers has faced ongoing operational pressures and financial difficulties, with continuous losses since 2018, totaling over 8.2 billion yuan [2] - For the first three quarters of 2025, the company reported revenues of 215 million yuan, a year-on-year decline of 46.08%, and a net loss of 114 million yuan, a significant drop of 168.15% year-on-year [2] - The company is experiencing a debt crisis, with overdue debts totaling 52.5 million yuan, exceeding 10% of the audited net assets for 2024 [2] Shareholder Situation - Wang Zhongjun's 154 million shares (48.54% of his total holdings and 5.55% of the total shares) are set for a second auction after the first auction failed [2] - Wang Zhongjun and Wang Zhonglei's combined shares have been 100% frozen, indicating significant pressure on the company's capital structure [2]

Group 1 - The core point of the article is that Haichuan Intelligent (300720.SZ) is facing a new share reduction plan from its major shareholders, which may lead to significant cash outflows for the company as the previous controlling family members plan to exit their positions [1][2][4] - Shareholders Wu Guifang and Zheng Xuefen plan to reduce their holdings by a total of 1,166,160 shares, representing 3% and 2.98% of the company respectively, with a potential cash inflow of up to 352 million yuan if the maximum reduction is executed [2][10] - Since 2021, the previous controlling family has cumulatively cashed out 1.551 billion yuan through multiple share reductions, indicating a trend of divestment from the company [1][4][13] Group 2 - Haichuan Intelligent is experiencing a decline in both revenue and net profit, with a reported revenue of 162 million yuan for the first three quarters of 2025, down 7.02% year-on-year, and a net profit of 27.618 million yuan, down 24.82% year-on-year [6][14] - The company's main business, which includes measurement equipment, has seen a slowdown in revenue growth, with the measurement equipment segment reporting negative growth in the first half of 2025 [6][14] - Five out of six subsidiaries of Haichuan Intelligent are currently operating at a loss, contributing to the overall financial strain on the company [7][15] Group 3 - The company has faced increased operating expenses, with sales and management expenses rising by 1.86% and 11.33% respectively in the first three quarters of 2025 [7][15] - Other income has decreased by 55.33% due to reduced government subsidies and software tax refunds, while investment income has dropped by 41.18% due to decreased principal and interest rate cuts [7][15] - As of September 2025, the company's inventory value has increased by 11.64% to 100 million yuan, which, along with increased asset impairment losses, has negatively impacted net profit [8][16]

Core Viewpoint - The announcement reveals that shareholder Cao Lianying plans to reduce his stake in Xingye Co., Ltd. by up to 2,620,800 shares, representing 1% of the company's total share capital, within three months following the disclosure of the plan [1] Group 1: Shareholder Reduction Plan - Cao Lianying intends to sell shares through centralized bidding and/or block trading, with the selling price determined by market conditions at the time of the sale [1] - The total cash-out from the planned reduction is approximately 41,094,144 yuan, based on the previous trading day's closing price of 15.68 yuan per share [2] - As of the announcement date, Cao Lianying directly holds 6,568,770 shares and indirectly holds 2,337,595 shares through Suzhou Baowo Venture Capital Co., Ltd., totaling 8,906,365 shares, which is 3.40% of the company's total share capital [2] Group 2: Shareholder Relationships and Impact - Cao Lianying is one of the controlling shareholders and actual controllers of the company, with established relationships with other key stakeholders, including Wang Jinxing and Wang Quanhong, due to familial ties [2] - The reduction plan is not expected to significantly impact the company's governance structure or ongoing operations, and it will not lead to a change in the company's control [2] Group 3: Previous Shareholder Reductions - On July 1, 2025, shareholder Shen Genzhen completed a reduction of 2,620,000 shares, also representing 1% of the total share capital, with a total amount of 36,532,486.10 yuan [3] - On October 11, 2025, shareholder Wang Jincheng reduced his stake by 2,620,800 shares, with a total amount of 41,540,657 yuan, at a price range of 15.65 to 16.19 yuan per share [3] Group 4: Fundraising Activities - On July 4, 2023, the company announced a plan to issue convertible bonds to unspecified investors, aiming to raise up to 750 million yuan for investment in a new materials project [3] - On April 26, 2024, the company extended the validity period of the shareholder meeting resolution regarding the issuance of convertible bonds until July 18, 2025 [3]

西安旅游公告，股东磐京股权投资基金管理（上海）有限公司－磐京稳赢6号私募证券投资基金于2025 年12月16日通过集中竞价交易方式减持公司股份12700股，占公司总股本的0.005364%。本次减持后， 磐京基金持有公司股份1183.73万股，占公司总股本的4.99997%，不再是公司持股5%以上股东。 ...

Core Viewpoint - The company announced that its controlling shareholder, Shi Huiqing, and his concerted party, Zhu Chunhua, reduced their shareholding by 2.104 million shares, accounting for 1.12% of the total share capital, between December 8 and December 17, 2025 [1] Summary by Relevant Sections - Shareholding Change - After the reduction, the combined shareholding of Shi Huiqing and his concerted parties decreased from 69.95% to 68.83% [1] - The change in equity ratio reached the 1% threshold [1] - Compliance with Regulations - The equity change does not violate any previously made commitments, intentions, or plans [1] - The reduction does not trigger any mandatory tender offer obligations [1]